BMS sees success in Phase III Sotyktu psoriatic arthritis trials - Yahoo Finance

December 23, 2024

Bristol Myers Squibb announced positive Phase III results for Sotyktu in psoriatic arthritis, showing greater treatment response vs. placebo. Sotyktu, an oral TYK2 inhibitor, is FDA-approved for plaque psoriasis and saw $170m in sales in 2023, projected to rise to $2.2bn by 2030.

Related Clinical Trials

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Highlighted Terms

NCT04908189 American College of Rheumatology US Food and Drug Administration Bristol Myers Squibb psoriatic arthritis Sotyktu NCT04908202 deucravacitinib

Related News

finance.yahoo.com

BMS sees success in Phase III Sotyktu psoriatic arthritis trials - Yahoo Finance